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The role of hepatic ﬁne-needle aspiration (FNA) biopsy has evolved. Advances in imaging modalities have obviated the need
for tissue conﬁrmation in most hepatocellular carcinomas (HCCs). There is risk of needle-tract seeding. Increasingly, small
nodulesarebeingdetectedonultrasoundsurveillanceofhigh-riskpatients.Diagnosticchallenges associatedwithcirrhosisinclude
distinctionofbenign hepatocellular nodules, namely, large regenerative nodules and dysplastic nodules, fromreactive hepatocytes;
anddistinctionofwell-diﬀerentiatedHCCsfrombenignhepatocellularnodules.Thispaperwilldiscuss(i)controversiesregarding
preoperative/pretransplantation FNA diagnosis of HCC, (ii) update of biological evolution, nomenclature, and histopathologic
criteria for diagnosis of precancerous nodules and small HCCs, and (iii) algorithmic approach to FNA diagnosis of hepatocellular
nodules. Optimal results depend on dedicated radiologist-cytopathologist team, on-site cytology service; combined cytohistologic
approach, immunohistochemistry, and clinicopathologic correlation. Hepatic FNA is likely to be incorporated as a point of care as
we move towards personalized medicine.
1.Introduction
The incidence of hepatocellular carcinoma (HCC) has risen
as a result of increased global burden of chronic liver disease
due to hepatitis B and C virus infections, aﬂatoxin B1,
alcoholism,andnonalcoholicfattyliverdisease/nonalcoholic
steatohepatitis associated with the metabolic syndrome. It is
now the sixth most common cancer worldwide and the third
mostcommoncauseofcancerdeaths[1].Thenaturalhistory
in high-risk patients is the occurrence of dysplastic foci in
a cirrhotic background from which precancerous dysplastic
nodules may ensue with some transforming to become HCC
[2, 3].
Much progress has been achieved over the years with
regard to detection/screening, diagnosis, surveillance, and
multimodal treatment approaches leading to improvement
in prognosis of HCC [4, 5]. Surgery, and in particular
liver transplantation, is considered the best option; but
this is not widely available, and many patients still present
with advanced disease. Increasing knowledge of molecular
hepatocarcinogenesis has led to the advent of molecular
targeted therapy [6]. Sorafenib, the antiproliferative and
antiangiogenic multikinase inhibitor, has broadened the
therapeutic horizon for advanced cases [5].
Early detection with appropriate therapy is still the
optimal approach that oﬀers the patient the best prognosis.
High-risk patients undergo 6-monthly ultrasound screening
and serum alpha-fetoprotein (AFP) assessment. Advances
in dynamic imaging techniques have increased the accuracy
of HCC diagnosis thus obviating the need for tissue con-
ﬁrmation [7–9]. The role of ﬁne-needle aspiration biopsy
(FNA) in the diagnosis of hepatocellular nodular lesions has
evolved over the years. Smaller and smaller nodules are being
detected on increasing surveillance of high-risk patients.
Accurate tissue characterization of small well-diﬀerentiated
hepatocellular nodular lesions (<2cm) is very challenging
and has signiﬁcant therapeutic implications.
There are two schools of thought with regards to preop-
erative/pretransplant FNA diagnosis of HCC. An update of
the biological evolution and histopathologic criteria for the2 Pathology Research International
diagnosis of dysplastic nodules, small HCCs and “nodule-
in-nodule” lesions is presented in tandem with clinically
relevant nomenclature. An algorithmic approach to FNA
diagnosis of HCC and hepatocellular nodular lesions is
outlined. Current issues, controversies, challenges and future
expectations are discussed. The focus is on hepatocellular
nodular lesions associated with cirrhosis.
2. Fine-NeedleAspirationBiopsyfromthePoint
of View of the Aspirator and Reader
“Can indeterminate diagnoses of highly well-diﬀerentiated
hepatocellular nodular lesions be reduced?”
2.1. The Technique. T h e r ea r ev a r i o u sr o u t e sf o rp e r f o r m i n g
FNAbiopsyoftheliver.Percutaneous(transabdominal)FNA
biopsy performed under computed tomography (CT) or
ultrasound (US) guidance has been adopted worldwide as
as a f e ,e ﬃcient, and minimally invasive procedure for the
diagnosis of focal liver lesions. It is useful for establishing
inﬂammatory/infective conditions to ruling out or con-
ﬁrming malignancies, helping to distinguish primary from
secondary lesions. This technique is especially advantageous
in patients with advanced malignancies or who are poor
surgical candidates. It can also be performed at laparoscopy
or laparotomy under direct vision. The sensitivity and
speciﬁcity of percutaneous FNA biopsy for detection of
liver malignancy have been reported to be around 90%
(range, 67%–100%) and 100%, respectively [9–11]. Sen-
sitivity varies according to factors such as blind versus
guided aspiration; number of passes; operator skill; size,
location and consistency of the lesion; quality of smears;
combined cytohistologic studies with ancillary testing; and
reader expertise. The positive and negative predictive values
and overall accuracy of FNA diagnosis for liver malignancy
were reported in one large study to be 100%, 59.1%, and
92.4%, respectively [9]. False positives are rare.
Endoscopic ultrasound-guided FNA (EUS-FNA) is the
latest diagnostic and staging tool. It is safe, accurate, and
versatilebuthighlyoperatordependent.EUS-FNAcanaccess
left lobe of liver, hilum, proximal right lobe, gallbladder,
extrahepatic biliary system, and perihilar lymph nodes.
It is especially useful for small and deep-seated left lobe
lesions below CT/MRI resolution or not easily accessible
to percutaneous FNA. As such, it enhances staging of liver
metastases [12], and facilitates early detection of multifocal
HCC in cirrhosis, thereby allowing for accurate assessment
of number of lesions (intrahepatic staging of HCC) for
transplantation eligibility purposes [13, 14]. Another advan-
tage is concurrent sampling of pancreas and liver lesions,
conﬁrming primary and metastatic malignancy in one single
diagnostic encounter. EUS-FNA has high sensitivity (82%–
94%) and speciﬁcity (90%–100%) for malignancy [15–
17]. However, as with percutaneous FNA, it gives a better
diagnosticyieldwithmetastasesthanwithwell-diﬀerentiated
hepatocellular nodular lesions.
The needle size is between 20 to 22 gauge. Aspiration
needles with cutting mechanism enable microbiopsy cores to
be procured. In some instances, FNA samples can be more
representative than wide-bore core needle biopsies because
although the cores are broader they are shorter, and the core
biopsy procedure is limited in ﬂexibility and accessibility.
With ﬁne needles, multiple aspirations (up to four passes)
can be safely performed in diﬀerent directions, provided
there are no contraindications.
2.2. Tissue Samples. The types of tissue samples obtained
with FNA technique include smears, needle rinse samples,
cell blocks, and microbiopsies from which core imprints can
be made. Smears are air-dried and stained with Diﬀ-Quik
and/or May-Gr¨ unwald-Giemsa (MGG) as well as ﬁxed in
95% alcohol and stained by the Papanicolaou method. To
overcome paucity of histologic material, particulate material
is quickly retrieved from the glass slides with a scalpel
prior to staining and formalin-ﬁxed for paraﬃn-embedded
cell block preparation. The resultant histologic sections
allow for study of architecture and for special stains and
immunohistochemistry. Immunocytochemical studies may
be necessary if only smears are available.
Liquid-based cytology (LBC) of ﬁne needle aspirates of
HCC is not routinely accepted. Potential advantages include:
(i) the aspirator can work alone putting the entire specimen
into preservative solution, thus solving the problem of cen-
tralized pathology services receiving highly variable quality
of sent-in smears; (ii) the smears are more representative as
everything is collected on one slide with a portion stored in
the permanent preservative solution for re-use when needed;
(iii) multiple smears and cell block can be prepared for
routine staining, immunostaining, and molecular tests; (iv)
better preservation of cells; (v) shorter screening time as cells
are concentrated in a 20-mm round area; and (vi) no inter-
ference from background elements [18–20]. Disadvantages
include: (i) no on-site assessment of adequacy (unless split-
sample method or double-aspiration protocol employed),
(ii) no triage of specimens, (iii) no air-dried smears for
Giemsa preparations, (iv) semiautomated processing requir-
ing longer preparation time, (v) loss of information from
removal of background elements, (vi) familiarity with cyto-
logic artifacts and recognition of diagnostic pitfalls to avoid
misinterpretations, and (vii) high cost. Under certain cir-
cumstances, smears of FNA material prepared by ThinPrep
method may not be representative. It has been postulated
that larger cell groups may settle out of the specimen so
rapidly that they are not sucked onto the ﬁlter; or the groups
may drop oﬀ the ThinPrep ﬁlter immediately after suction is
removed and not be transferred to the prepared slide.
Intheauthor’sexperience(unpublisheddata)withThin-
Prep method for aspirates of HCC, the background tends to
be devoid of red blood cells, debris, and bile; however, tumor
diathesis, if excessive, is still discernible. The cellularity is
much lower per slide than in conventional smears. The cell
aggregates tend to be tighter, 3-dimensional, and decreased
in size with partial/complete loss of cytoarchitecture, such
as, arborizing trabecular structures, pseudoacinar rosettes,
and peripheral and transgressing endothelium. Tumor
cells appear generally smaller with nondescript/“angulated”
shapes, denser cytoplasm, and frayed cell borders. Chro-
matin details, nucleoli, and intranuclear inclusions are morePathology Research International 3
deﬁned but diﬃcult to appreciate in cells that are not
monolayered. Cell blocks can be prepared from liquid-based
specimens with reasonable quality; however, integrity of the
trabecular-sinusoidal arrangement may be compromised.
Immunocytochemistry can be successfully applied to thin-
layer cytology slides [20]. However, just as in conventional
smears, immunocytochemical interpretation can be an issue,
especially in smears with low yield, dispersed cellularity, and
obscured nuclear details. The general impression is that it is
more challenging to decipher the cytologic characteristics of
HCC in LBC material than on conventional smears.
2.3. Diagnostic Challenges. The diagnostic challenges in FNA
of focal liver lesions are (i) distinction of benign hepato-
cellular nodular lesions, namely, large regenerative nodule,
dysplastic nodule, focal nodular hyperplasia, and hepatocel-
lular adenoma from reactive hepatocytes; (ii) distinction of
well-diﬀerentiated HCC from benign hepatocellular nodu-
lar lesions; (iii) distinction of poorly diﬀerentiated HCC
from cholangiocarcinoma and metastatic carcinomas; (iv)
determination of histogenesis of malignant tumor; and (v)
determination of site of origin of malignant tumor [21]. At
the well-diﬀerentiated end of the spectrum, cytohistologic
features of malignancy are lacking whilst at the poorly
diﬀerentiated end, clues to the cell lineage are found wanting
(see Section 6).
2.4. Ways to Improve Accuracy Rates of FNA Biopsy Diagnoses.
Optimal results are obtained with dedicated and experi-
enced team comprising aspirator (radiologist- or endosono-
grapher) and reader. An on-site cytology service with a
cytopathologist or well-trained cytotechnologist is ideal [22,
23]. The service provides for rapid Diﬀ-Quik-stained smears
for assessment of sample adequacy, retrieval of particulate
tissue for cell blocks, and triage of specimens for culture,
ﬂowcytometryandotherancillarytests,includingmolecular
analysis. A combined cytohistologic approach is highly
recommended with cell blocks and microbiopsies [24–26].
Immunohistochemistry has a great adjunctive role. The ﬁnal
diagnosis should be based on close clinicopathologic cor-
relation. Resources should be provided to support training
of cytotechnologists as well as for continuing professional
development.
3. FineNeedleAspirationBiopsyfromthePoint
of View of the Hepato-Oncology Team
“To perform or not to perform FNA biopsy for conﬁrmation of
diagnosis?”
The last decade has seen much active debate over the
role of FNA in the detection of HCC [7, 9, 27]. Advances
in dynamic imaging techniques have increased the accuracy
of HCC diagnosis. Recognition of the diagnostic value of
contrast washout allowed for the reﬁnement of the European
Association for the Study of Liver 2000 Conference (EASL)
guidelines and is reﬂected in the American Association
for the Study of Liver Disease (AASLD) guidelines [7,
8]. Nodules larger than 2cm occurring in cirrhotic livers
are diagnosed as HCC if they show characteristic intense
arterial proﬁle with contrast washout in delayed venous
phaseononedynamicimagingmodality.Nodulesmeasuring
between 1 and 2cm in cirrhotic livers require concurrence
of two coincidental imaging modalities; otherwise, biopsy is
recommended. The dilemma is whether to biopsy nodules
< 1cm. The EASL guidelines recommend the “wait and see”
policy with 3-monthly US surveillance.
Those who oppose the performance of FNA biopsy cite
the following reasons.
(1) Advances in Dynamic Imaging Techniques are Sensitive
and Accurate Enough for Establishing an HCC Diagnosis in
most Nodules. Advances in dynamic imaging modalities,
such as contrast-enhanced US and dynamic magnetic reso-
nance imaging (MRI), have yielded an accuracy, sensitivity,
and speciﬁcity of 99.6%, 100%, and 98.9%, respectively, for
the diagnosis of HCC [28]. The demonstration of an inten-
siﬁed contrast-enhanced arterial phase followed by delayed
venous washout pattern is pathognomonic of HCC, thus,
obviating the need for tissue conﬁrmation. However, false
positives do occur. According to Ghittoni et al, a diagnostic
protocol based on imaging is like “a boat that leaks like
a sieve.” Intrahepatic cholangiocarcinoma may occasionally
have a hypervascular imaging pattern mimicking HCC
[29]. False negatives are more likely to happen, especially
with insuﬃcient neoarterialization of small hepatocellular
nodules. Many of these nodules may prove to be malignant
in the long run.
(2)Adoptthe“WaitandSee”PolicyforHepatocellularNodules
Measuring <1cm. The current EASL and AASLD guidelines
are to biopsy nodules between 1 to 2cm if no deﬁnitive
diagnosis of HCC is reached on two coincidental imaging
modalities, and to adopt the “wait and see” policy with more
frequentUSsurveillancefornodules<1cm[7,8].Smallwell-
diﬀerentiated hepatocellular nodular lesions associated with
cirrhosis range from large regenerative nodule, to low- and
high-grade dysplastic nodules and small HCCs (early and
progressed types) [30]. Studies on the biological evolution
of small HCCs reveal that they tend to start oﬀ as dysplastic
foci of hepatocytes exhibiting large cell or small cell change.
Large cell change is detected in up to 81% of cirrhotic
liver explants [31]. The incidence of small cell change in
cirrhotic livers varies considerably ranging up to 50% in
explants [31]. These abnormal foci may develop into low-
grade (with large cell change) and high-grade (with small
cell change) dysplastic nodules. The precancerous nature of
smallcellchangeissupportedbyhighproliferativeactivityin
the hepatocytes and morphologic resemblance to early HCC
[2].
Malignant transformation may occur in dysplastic or
even regenerative nodules giving rise to nodule-in-nodule
lesions. High-grade dysplastic nodules become malignant in
a third of cases [32]. Cytodiagnosis of these small nodules
and the distinction of high-grade dysplastic nodule from
early HCC are extremely challenging even with the aid of
reticulin stain and novel immunohistochemical markers.
Although the speciﬁcity of FNA for HCC is close to 100%, its
negativepredictivevalueislow.Hence,patientswithnegative4 Pathology Research International
biopsy ﬁndings should either undergo a second biopsy or
enhanced surveillance [33].
It is the opinion of Caturelli et al that the prognostic
implicationsofearlydiagnosisandtreatmentofHCCcannot
justify this policy of “masterly inactivity” [27]. Firstly, it
is incongruous to work on increasing detection of small
nodulesinhigh-riskpatientsandthenrecommend“masterly
inactivity.” Secondly, more than half of the nodules < 1cmin
cirrhotic livers prove to be HCCs (68%). Thirdly, US-guided
FNA biopsies of hepatic nodules <1cm in experienced hands
with use of novel biomarkers and interpreted by expert
reader yield correct diagnoses in about 90% of cases [34].
(3) Risk of Needle-Tract Seeding. The most contentious
complication cited by detractors of the technique is the risk
of needle-tract seeding turning a potentially operable case of
HCC to a metastatic state [28]. Risk of implantation metas-
tasesafterbiopsyformalignancyingeneralisconsideredrare
(0.003–0.009%); the incidence for HCC varies from 0.003%
to 5% [34–36]. An overall incidence of 0.13% of HCC
with soft tissue metastases was reported in one large study
whereatotalof18,227person-times ofFNAorpercutaneous
ethanol injection was performed on HCC patients [37].
The estimated rates of 18 and 22G needle-induced seeding
for HCC were 0.60% and 0.11%, respectively [37]. The
interval between detected seeding and biopsy varies from
several months to 3 years. Whilst some studies have shown
that preoperative FNA has no statistically adverse eﬀect on
the operability, possibility of tumor spread, or long-term
survival of HCC patients [38, 39], there are others which
strongly maintain that pretransplant FNA diagnosis of HCC
is not necessary [40, 41]. Seeding is usually noted with
subcapsular tumors and those of high-grade malignancy;
these tend to be tumors >2cm. Hence, FNA of nodules 1 to
2cm may be fairly free of seeding, and if these turn out to be
HCC, they tend to be well diﬀerentiated.
(4)RiskofIntraperitonealBleeding. Themajorcauseofdeath
after percutaneous FNA is bleeding, mostly associated with
severecirrhosiswithcoagulopathyorlargesuperﬁcialtumors
notcoveredbynormalliverparenchyma[9].Amortalityrate
of 0.018% was reported in a multi-institutional Italian series
of 10,766 US-guided FNA biopsies [42]. Risk of bleeding is
not a controversial contraindication.
(5) Increased Risk of Tumor Recurrence and Posttransplanta-
tionRecurrence. Thereisnoclearevidencethat,independent
of tumor stage, patients who undergo FNA biopsy are at
higher risk of tumor recurrence and posttransplantation
recurrence due to biopsy-induced hematogenous dissem-
ination of tumor cells [34, 36, 43]. It is possible that
microinvasive tumor cell dissemination may have occurred
prior to the procedure. Metachronous tumors may also arise
from the residual oncogenic cirrhotic liver [4].
Those in favor of performing preoperative/pretransplant
FNA cite the following reasons:
(1) Serum AFP Has Low Sensitivity. Serum AFP is the
most commonly used serum biomarker in conjunc-
tion with US in screening programs. It has low sensi-
tivity (45%) [44], and the level has to be signiﬁcantly
elevated (400ug/L) to be of any value as a screening
tool. It is also usually not elevated in patients with
small HCCs. Hence. It is prudent to perform FNA so
as not to miss an early case of HCC. Development of
novelserumsurrogatemarkers,suchas,glypican-3(a
membrane proteoglycan) could prove useful [45].
(2) T oA lla yP atientA nxietyOnceaL iverN oduleH asBeen
Detected on Imaging.
(3) T oC u tD o w no nC o s t so fL o n g - T e r mI m a g i n gS u r v e i l -
lance in the Long Run.
(4) To Avoid a Futile Transplantation. False-positive
results from imaging techniques have occurred. The
conundrum is to balance the risk of unnecessary
surgery (2.5%) [28] against the risk of needle-tract
seeding. The risk of seeding is overall lower than that
of a futile transplantation with its attendant risks and
life-long ﬁnancial and medical issues.
(5) Eligibility for Liver Transplantation. Liver transplan-
tation provides the best overall outcome in that it
removes the possibility of metachronous lesions in
a cirrhotic liver and restores liver function. Pre-
transplantation biopsy is strongly recommended for
transplantation listing, if HCC is the only reason
for transplant in a compensated cirrhotic case [33].
In fact, the conﬁrmation of HCC favorably alters
the patient’s candidacy for liver transplantation.
A previous biopsy should not be considered a
contraindication for transplantation. Although the
speciﬁcity of FNA for HCC is close to 100%, its
negative predictive value is low. Hence, patients with
negative biopsy ﬁndings should either undergo a
second biopsy or enhanced surveillance [33].
(6) ForImmediateInstitutionofAnti-HCCTherapyWhen
Lesion Is Still <2cm. The 5-year survival rate of early
HCC is twice as high as that of progressed HCC [32].
It has been documented that 80% of small HCCs
are already progressed and moderately diﬀerentiated
with microinvasion of portal vein radicles (27%) and
minute intrahepatic metastases or satellites (10%)
at time of diagnosis [3]. Furthermore, 80% of
patients with microinvasion and/or satellitosis suﬀer
recurrence within the ﬁrst 2 years of followup after
surgery.Insuchcases,itwouldbeprudenttoperform
FNA biopsy early, particularly in high-risk patients,
so as not to miss that small window of opportunity
for chance of cure.
(7) F o rA p p r o p r i a t eT h e r a p yi nN o n - H C CC a s e s .I fr e s e c -
tion appears to be the best option, biopsy may or
may not be performed. When palliative treatment is
planned, biopsy is recommended to avoid unneces-
sary/inappropriate treatment [46].
(8) Use of Coaxial Technique of Biopsy May Reduce Risk of
Seeding. A coaxial technique allows multiple samples
to be obtained without repeated placement of thePathology Research International 5
needle; thus, potentially reducing the risk of needle-
tract seeding. This approach helps to reduce the
number of inadequate biopsies and is preferred for
small and distant lesions. It is highly recommended
but has yet to be evaluated [47].
(9) FNA Biopsy as Point of Care. Practices are likely
to change. Prognostic factors to determine survival
and recurrence rate include tumor size, localiza-
tion, number of nodules, satellitosis, vascular inva-
sion, and histologic grade. Tumor diﬀerentiation
and vascular invasion show a strong correlation.
Despite a potential bias due to sampling errors,
FNA biopsy might help identify patients having
well-diﬀerentiated HCCs with low risk of vascular
invasion and good prognosis after transplantation.
Muchresearchisbeingdoneingenomicsandproteomics
to determine the molecular signatures of HCCs. With the
advent of molecular testing for better clinical tools for
screening, diagnosis, surveillance, prediction of eﬃcacy of
treatment, monitoring of response, prognostication, and for
rationaltargetedtherapies,itisforeseenthatFNAbiopsy will
be the most minimally invasive technique available to obtain
samples of tumor and peritumoral tissues for molecular
proﬁling [5, 6].
The issues that need to be addressed by hepatology teams
were aptly put by Sch¨ olmerich and Schacherer [46], as:
(i) how good is the technique and which is the preferred
technical modality to perform a biopsy [eﬃcacy of imaging-
guided FNA], (ii) how dangerous is such a procedure and
does it interfere with later treatment [complications and
treatment options], and (iii) is a biopsy necessary and does
it change the outcome [need for biopsy]? In the meantime,
however, to biopsy or not to biopsy is a bedside decision
to be made by the hepatology team, depending on the
treatment options available. In developing/less developed
countrieswherepatients tendtopresentwithmoreadvanced
disease, the practice of percutaneous US-guided FNA is still
popular due to cost eﬀectiveness, nonavailability of state-of-
the-art imaging technologies, limited treatment options, and
individual preference and expertise.
4. Nomenclature and Biological Evolution of
PrecancerousLesionsinCirrhosis
Small hepatocellular nodules (≤2cm) can occur in cir-
rhotic or noncirrhotic livers. They comprise large regener-
ative nodules, dysplastic nodules, and small HCCs. Focal
nodular hyperplasia and hepatocellular adenoma are well-
diﬀerentiated hepatocellular nodular lesions occurring in
noncirrhotic livers and will not be discussed in this review.
Recentstudiesonthebiologicalevolutionofhepatocellu-
lar nodules in cirrhosis have led to establishment of clinically
relevant nomenclature for precancerous lesions and small
HCCs [2, 6, 30]. Large cell change (“liver cell dysplasia”)
is deﬁned as hepatocytes displaying corresponding nuclear
andcellularenlargementwithpreservednuclear-cytoplasmic
ratio. Small cell change (“small cell dysplasia”) is deﬁned
as hepatocytes exhibiting decreased cytoplasmic volume,
cytoplasmic basophilia, mild nuclear pleomorphism, hyper-
chromasia, and increased nuclear-cytoplasmic ratio, giving
animpressionofnuclearcrowding/increasedcellulardensity.
T h e s eg r o u p so fa b n o r m a lh e p a t o c y t e sa r er e f e r r e dt oa s
dysplastic foci if they are <1mm and dysplastic nodules if
they are >1mm in size. Dysplastic nodules can be low grade
(large cell change) or high grade (small cell change). The
precancerous nature of large cell change is still debatable. On
the other hand, a high-grade dysplastic nodule indicates an
increased risk for carcinoma development.
Small HCCs (≤2cm) are further categorized into early
HCC (well-diﬀerentiated HCC with indistinct margins) and
progressed HCC (well- to moderately diﬀerentiated HCC
with distinct margins) [3, 30]. Distinctly nodular small
HCCs usually contain well-developed unpaired arteries.
Early HCCs may contain both portal tracts and unpaired
arteries; similar features may be found in high-grade
dysplastic nodules. Identiﬁcation of high-grade dysplastic
nodulesand/orsmallHCCsshouldleadtotreatmentbylocal
ablation, surgical resection or transplantation.
Awareness of the current morphologic criteria for the
diagnosis of early HCC is helpful for the interpretation
of small histologic samples and for choice of appropriate
immunohistochemical panel. Early HCCs are characterized
by the following histologic features [2, 30]: (i) increased
cell density >2 times that of the surrounding tissue, with
an increased nuclear-cytoplasmic ratio, (ii) irregular thin
trabecular pattern (2 cells or more thick), (iii) pseudoglan-
dular pattern, (iv) unpaired arteries, (v) diﬀuse fatty change,
(vi) cytoplasmic basophilia or eosinophilia, (vii) sinusoidal
capillarization, (viii) invasion of intratumoral portal tracts,
a n d( i x )s t r o m a li n v a s i o na c c o m p a n i e db yl a c ko fd u c -
tular reaction at the periphery of the nodules. Malignant
transformation can occur within dysplastic or regenerative
nodules, where any of the above features may be restricted
to an expansile subnodule in the parent nodule (“nodule-
in-nodule”). Under such circumstances, several passes in
diﬀerent directions during the FNA procedure may be
required to overcome the focality of these proliferative foci.
Fatty change, which can be observed in any hepatocel-
lular nodular lesion, is reported in 40% of early HCC [6].
Prevalence of fatty change decreases along with increasing
tumor size as neoarterialization increases. Sinusoidal capil-
larization is present diﬀusely in HCC and diﬀusely/focally in
high-grade dysplastic nodule. Stromal invasion is the most
helpful feature in diﬀerentiating early HCC from high-grade
dysplasticnodule.Microinvasionofportalveinradiclesisnot
expectedinearlyHCCbutmaybeencounteredinprogressed
HCC.Microbiopsiesallowforassessmentofarchitectureand
stromal invasion.
5.ClinicalImplicationsof Molecular
Subclassiﬁcationof Hepatocellular
Carcinoma
Hepatocellular carcinoma has a complex molecular patho-
genesis and morphologic heterogeneity. Genomic and pro-
teomic studies have helped elucidate the molecular signa-
tures of HCCs. Recent studies have also identiﬁed molecular6 Pathology Research International
Figure 1: FNA of cirrhosis. Hyperplastic hepatocytes occur in 2-
cell thick cords with closely adherent bile ductule. The polygonal
hepatocytes exhibit cellular polymorphism with well-deﬁned cell
borders, ample granular cytoplasm, central round nucleus, and
nuclear-cytoplasmic ratio of about 1/3. The ductule, indicative of
hepatocellular-stromalinterfacerestoration,consistsofoverlapping
rows of small, ovoid, darkly-staining nuclei with nondiscernible
cytoplasm. (Giemsa, ×400).
changes in HCC which are potential markers of early HCC,
such as glypican-3. Furthermore, a speciﬁc gene-expression
signature of the peritumoral liver tissue was found to
correlate with late recurrence and survival [48]. A molecular
subclassiﬁcation will soon be added to the conventional
morphologic classiﬁcation; the purpose of which is to iden-
tify predictors of aggressive/indolent behavior or features
associated with sensitivity/resistance to novel therapies [6].
The future role of pathologists will be to interrogate the
tumor and the peritumoral tissues and to be able to interpret
this situation for clinical use. Apart from the main objective
of developing personalized molecular targeted anticancer
treatment protocols, such an approach will also help to iden-
tify patients at high risk for recurrence/further development
of cancer. This will allow for selective intensiﬁed clinical
followup with possible chemopreventive strategies (person-
alizedpreventivemedicine)[5].Thecombinationofmultiple
targeted agents is the next logical step in the treatment of
HCCduetothestrongrationaletoinhibit asmanysignalling
pathways as possible in hepatocarcinogenesis [49]. This is
also useful for further treatment of sorafenib-resistant cases.
What all this translates into on the practical front is that
tissue samples will have to be procured from various parts of
thetumor,andininoperablecases,theFNAbiopsytechnique
provides the best approach to date for tissue procurement.
6.Algorithmic Approachto FNA
DiagnosisofHCCandAssociated
Hepatocellular Nodular Lesions
Well known for its heterogeneity, HCC has variants and
mixed lesions that may mimic other tumors. On the other
hand, metastases to the liver are by far commoner than
primary liver cancers. Apart from cystic and inﬂammatory
Figure 2: FNA of hepatocytes with large cell change. Two-cell-
thick rows of hepatocytes show corresponding cellular and nuclear
enlargement, maintaining normal nuclear-cytoplasmic ratio. Cel-
lular polymorphism amongst sibling cells is clearly evident. Note
intranuclear inclusions. Contrast with group of normal-sized
hyperplastic hepatocytes (Papanicolaou, ×200).
conditions, the major diagnostic issues in FNA of focal
liver lesions are highlighted in Section 2 under “Diagnostic
challenges” [21].
6.1. FNA Biopsy of Benign Hepatocellular Nodular Lesions.
Aspirates of cirrhotic nodules, including large regenerative
nodules, show a polymorphous population of cells, com-
prising hyperplastic hepatocytes, bile ductal epithelium,
endothelial cells, and Kupﬀer cells, accompanied by features
ofregenerationandrepair(Figure 1)[26,50].Polygonalhep-
atocytes have well-deﬁned cell borders, ample granular cyto-
plasm, central round nuclei with well-deﬁned nuclear mem-
brane, granular chromatin, and distinct nucleolus. Nonneo-
plastic hepatocytes exhibit polymorphism, that is, sibling
cells display variation in cell size and shape with correspond-
ing variation in nuclear size. The nuclear-cytoplasmic ratio
is about 1/3 (if one were to eyeball the nuclear and cell
diameters). Hyperplastic hepatocytes show binucleate forms
and appear as short 2-cell thick cords rather than singly.
Fatty change, when present, is best appreciated in Giemsa
preparations as intracytoplasmic vacuoles or as dispersed
bubbles leaked from ruptured cells. Bile ductal epithelium
appears as small ﬂat clusters of cohesive uniform cells with
minimal pale cytoplasm and bland, equidistant round to
ovoidnuclei,andlackingnucleoli.Bileductularepitheliumis
indicative of parenchymal-stromal interface restoration, and
its recognition in lesional material is tantamount to conﬁrm-
ing the benign status of the hepatocellular nodular lesion.
Bile ductules appear as curved double-stranded rows of
epithelial cells exhibiting ovoid darkly-staining overlapping
nuclei with nuclear disarray, high nuclear-cytoplasmic ratio
and barely visible cytoplasm, mimicking adenocarcinoma.
Elongatedendothelialandcomma-shapedKupﬀercellnuclei
can be identiﬁed amongst the hepatocytes. Inﬂammatory
cells, comprising predominantly of lymphocytes, and stro-
mal fragments may be encountered in the background. Focal
nodular hyperplasia gives similar restoration features.Pathology Research International 7
Figure 3: FNA of hepatocellular carcinoma. Low magniﬁcation view shows granular trails of irregularly shaped tumor aggregates (Giemsa,
×40).
Figure 4: FNA of moderately diﬀerentiated hepatocellular carcinoma. Broad tongues of cohesive malignant hepatocytes wrapped by
peripheral endothelium (Papanicolaou, ×400).
Aspirates of low-grade dysplastic nodules contain hepato-
cytes exhibiting large cell change with no/minimal nuclear
atypia and normal nuclear-cytoplasmic ratio (Figure 2).
Hepatocytes from high-grade-dysplasticnodulesaresmalland
monotonous with subtle increase in nuclear-cytoplasmic
ratio; the nuclear size is fairly similar to that of normal
hepatocytes but there is less cytoplasm, thus imparting an
impression of nuclear crowding [51]. Dysplastic hepatocytes
generally occur singly or in 1- to 2-cell thick cords. Fatty
change may be present. Bile ductal and ductular epithelium
and stromal fragments may be evident in the background.
It is diﬃcult to distinguish high-grade dysplastic nodule and
early HCC purely on cytologic grounds.
6.2. FNA Biopsy of Classic Hepatocellular Carcinoma. Hepa-
tocellular carcinomas are highly heterogeneous tumors with
regard to diﬀerentiation, histologic patterns (trabecular-
sinusoidal, pseudoacinar, and compact types), and cell
morphology. As such, one should be fully cognizant of the
challenges and limitations of FNA biopsy in the diagnosis
of HCC. Several passes in diﬀerent directions should be
performed in large tumors to overcome diagnostic diﬃ-
culties due to sampling bias. Accurate distinction of HCC
and its variants from metastases is crucial for institution of
appropriate therapy.
Cytologic features of HCC include [50]:
(i) Hypercellular smears composed of trails of tumor cell
clusters imparting a granular pattern of spread evident
on gross inspection (Figure 3).
(ii) Irregular arborizing, broad, tongue-like cords (>2c e l l s
thick) of cohesive malignant hepatocytes (Figure 4).
(iii) Peripheral endothelium wrapping broad cords (Figure
4).
(iv) Transgressingendotheliumrunningacrosslargeraggre-
gates (Figure 5(a)): basement membrane material
lookinglikepink“tramlines”(indicativeofsinusoidal
capillarization) is best seen in Giemsa preparations.
(v) Cohesion is the rule: tendency to dissociation is
observed in highly well-diﬀerentiated HCC due to
narrow cords; and in poorly diﬀerentiated HCC
where there is virtually absent reticulin.
(vi) Pseudoacini containing bile or pale secretions (Figure
5): polygonal neoplastic hepatocytes surround cysti-
cally dilated canaliculi.8 Pathology Research International
(a) (b)
(c)
Figure 5: FNA of well-diﬀerentiated hepatocellular carcinoma. (a) Malignant hepatocytes exhibit pseudoacinar pattern with blackish bile
plugs. Note transgressing endothelium with pink basement membrane material traversing tumor cells (Giemsa, ×200). (b) Rosette-like
clusters of malignant hepatocytes form pseudoacini with blackish bile plugs within the dilated bile canaliculi. Some intracytoplasmic bile
droplets are evident (Giemsa, ×400). (c) Similar pseudoacini are surrounded by malignant hepatocytes. The polygonal cells exhibit well-
deﬁned cell borders, ample granular cytoplasm, central round nucleus with well-deﬁned nuclear membrane, distinct nucleolus and granular
chromatin (Papanicolaou, ×400).
(vii) Hepatocytic characteristics include polygonal cells with
well-deﬁned cell borders, ample dense granular cyto-
plasm,increasednuclear-cytoplasmicratio(>1/3),cen-
tral round nucleus, well-delineated nuclear membrane,
prominent nucleolus, and ﬁne, irregularly granular
chromatin. M i t o s e si n c r e a s ew i t hn u c l e a rg r a d e(Fig-
ures 5(b) and 5(c)): cytologic features of malignancy
are wanting at the well-diﬀerentiated HCC end
whereas clues to hepatocytic histogenesis are lacking
at the poorly diﬀerentiated end.
(viii) Tumor cells may be smaller, larger, or of the same
size as nonneoplastic hepatocytes (Figure 6): well-
diﬀerentiated HCC cells tend to be conspicuous by
theirsmallsize,monotony,subtleincreaseinnuclear-
cytoplasmic ratio and nuclear crowding. Poorly
diﬀerentiated HCC cells tend to be pleomorphic
with thin nuclear membranes and irregular nuclear
contours.
(ix) Atypical bare hepatocytic nuclei may abound (Figure
7).
(x) Multinucleated tumor giant cells may be of “osteoclas-
tic” or pleomorphic type (Figure 8): the former shows
nuclear features akin to sibling tumor cells. Tumor
giant cells may be found even in the lower grades of
HCC. Their presence does not necessarily upgrade
the tumor.
(xi) Bile may be present within tumor cells or in canaliculi
or pseudoacini (Figure 5): bile appears as greenish-
black intracytoplasmic droplets, ropey intracanalic-
ular strands and blobs within pseudoacini; best
detected in Giemsa-stained smears.
(xii) Intracytoplasmic fat and glycogen vacuoles are com-
mon. Intracytoplasmic inclusions include hyaline, pale,
and Mallory bodies (Figure 7). Intranuclear cytoplas-
mic inclusions are not speciﬁc.
(xiii) Bile duct epithelial cells, if present, are few and
far apart. Background may be hemorrhagic and/or
necrotic.
Classic HCC is cytologically graded into well, moderately
and poorly diﬀerentiated lesions based on nuclear grade.Pathology Research International 9
(a) (b)
(c)
Figure 6: FNA of hepatocellular carcinoma. (a) Two populations of malignant hepatocytes are seen. One population forms a distinct broad
trabecula with peripheral endothelium. The other tumor cells are bigger, more pleomorphic, and less cohesive (Papanicolaou, ×200). (b)
The more pleomorphic cells appear discohesive but still retain recognizable hepatocytic characteristics. Note transgressing endothelium
(Papanicolaou, ×400). (c) Cell block shows trabecular-sinusoidal and pseudoacinar patterns. (H&E, ×200).
Well-diﬀerentiated HCC (Figure 9): Tumor cells closely
resemble nonneoplastic hepatocytes in size, shape and nuc–
lear and nucleolar appearances. The nuclear-cytoplasmic
ratio is slightly higher. Mitoses are exceptional.
Moderately Diﬀerentiated HCC (Figure 4). Tumor cells
bear a resemblance to nonneoplastic hepatocytes. The nuc-
lear-cytoplasmic ratio is moderately high, the round to ovoid
nuclei show moderate degrees of pleomorphism, nucleoli are
prominent, and mitoses are identiﬁable.
Poorly Diﬀerentiated HCC (Figure 8). There is poor rese-
mblance to hepatocytes. Tumor cells exhibit marked pleo-
morphism, less cytoplasm, very high nuclear-cytoplasmic
ratios, thinner nuclear membranes with irregular nuclear
contours, hyperchromasia, and numerous mitoses. Nucleoli
may be prominent or absent. Multinucleated tumor giant
cells are easily identiﬁed.
Cell Block/Microbiopsies. The histologic diagnosis of HCC
is based on cyto-architectural features, such as cell atypia,
cell crowding, trabecular thickness, and microacini. Estab-
lishment of trabeculae ≥3 cells thick is one of the most
helpful features in diagnosis of highly well-diﬀerentiated
HCC. Gomori’s silver stain for reticulin ﬁbers is useful in
distinguishing HCC from benign hepatic processes [52].
The reticulin framework is abnormal or deﬁcient in HCC,
and this coupled with the presence of broad cords accounts
for their friability during the retrieval process for cell
block preparation. Immunohistochemistry plays a helpful
adjunctive role.
6.3. FNA Biopsy of Variants of Hepatocellular Carcinoma.
Adequate representative sampling to achieve accurate cyto-
diagnosis of this heterogeneous malignancy will become
more crucial when molecular subclassiﬁcation of HCC
is implemented for targeted therapy. The variations and
variants of HCC include [53] the following.
(i) HCC with Fatty Change (Figure 10). Fatty change can
occur in all sizes and grades of HCC. Highly well-
diﬀerentiated HCC with fatty change can easily be
overlooked for nonneoplastic hepatocytes from fatty
liver or focal fatty change [50, 54].10 Pathology Research International
Figure 7: FNA of hepatocellular carcinoma. Atypical bare nuclei
exhibit characteristic hepatocytic nuclear features. Mallory hyaline
is seen as reddish clumpy intracytoplasmic material. Cross-section
of a broad trabecula bordered by peripheral endothelium is evident
(Papanicolaou, ×200).
(a)
(b)
Figure 8: FNA of poorly diﬀerentiated hepatocellular carcinoma.
(a) Two populations of tumor cells are seen. The better diﬀer-
entiated component is represented by a trabecula of malignant
hepatocytes with peripheral endothelium. The other population
consists of highly pleomorphic tumor cells with giant cells and
bizarre nuclei; there is no apparent resemblance to hepatocytes
(Papanicolaou, ×200). (b) Highly pleomorphic tumor giant cells
exhibit multinucleation, bizarre nuclei, and hyperchromatism
(Papanicolaou, ×400).
Figure 9: FNA of well-diﬀerentiated hepatocellular carcinoma.
Small-sized malignant hepatocytes exhibit monotonous appear-
ance with tendency to dissociation. The cells display well-
deﬁned cell borders, decreased dense cytoplasm, slightly eccentric
nuclei, increased nuclear-cytoplasmic ratio, and impression of
nuclear crowding. Transgressing endothelium abound (Papanico-
laou, ×200).
(a)
(b)
Figure 10: FNA of hepatocellular carcinoma with fatty change.
(a) Malignant hepatocytes exhibit intracytoplasmic fat vacuoles
of varying sizes. Lipid-containing bubbles are observed in the
background (Giemsa, ×400). (b) Cell block shows fatty change in
the tumor cells (H&E, ×200).Pathology Research International 11
(a)
(b)
Figure 11: FNA of hepatocellular carcinoma with sarcomatoid
change.(a)Looselycohesivehighlypleomorphictumorcellsexhibit
sarcomatoid features. Note transgressing endothelium (Giemsa,
×400). (b) Spindle-shaped tumor cells and tumor giant cells bear
no resemblance to hepatocytes. Transgressing endothelium abound
(Papanicolaou, ×400).
(ii) HCC with Clear Cell Change. Malignant hepatocytes
with glycogen-laden cytoplasm display a pale/clear
bubbly appearance, best appreciated in Giemsa
preparations [55].
(iii) HCC with Small Cell Change. The small tumor cells
show scanty cytoplasm, round nuclei, high nuclear-
cytoplasmic ratio, granular chromatin and small
nucleolus. They mimic neuroendocrine tumors with
a similar tendency to dissociation and microacinar
formation [56, 57]; however, the “salt and pepper”
chromatin of endocrine tumor cells is absent. Closer
scrutiny of all available material may reveal more
classic HCC features.
(iv) HCC with Pleomorphic Features. The pleomorphic
tumor cells are poorly diﬀerentiated with a ten-
dency towards dissociation. Scattered multinucleated
tumor giant cells and necrosis may be present.
(a)
(b)
Figure 12: FNA of highly well-diﬀerentiated hepatocellular
carcinoma from a “nodule-in-nodule” lesion. (a) Small and
monotonous malignant hepatocytes exhibit decreased dense cyto-
plasm, central to slightly eccentric nuclei, increased nuclear-
cytoplasmic ratio, and impression of nuclear crowding with closer
inter-nucleardistances.Transgressingendotheliumispresent.Cyto-
logic features are diﬃcult to distinguish from those of a high-grade
dysplastic nodule with small cell change. (Papanicolaou, ×200) (b)
Two populations of dissociated hepatocytes are present. The malig-
nant cells have dense eosinophilic cytoplasm with higher nuclear-
cytoplasmic ratio. The nonneoplastic cells from the parent nodule
have ample paler cytoplasm and normal nuclear-cytoplasmic ratio
(Papanicolaou, ×200).
(v) HCC with Spindle Cell Features (Figure 11). The
pleomorphic spindle-shaped cells are indistinguish-
able cytologically from sarcomatous cells [58]. (see
Sarcomatoid variant of HCC).
(vi) HCC with Giant Cell Features (Figure 11). This pure
variant is rare and has to be distinguished from giant
cell sarcomas. Bizarre multinucleated giant cells with
highly abnormal mitoses are present.
(vii) HCC with Biliary Diﬀerentiation. Some HCCs may
contain tubular spaces surrounded by columnar
cells with basal palisading nuclei, favoring true
acinar diﬀerentiation. HCCs may exhibit focal CK19
positivity—this may imply poorer prognosis [59].
Such HCCs have to be separated from the rare mixed
type of HCC-CC.12 Pathology Research International
(a)
(b)
(c)
Figure 13: FNA of metastatic adrenocortical carcinoma to the
liver. (a) Cohesive group of tumor cells with ample cytoplasm,
central round nucleus, distinct nucleolus, and granular chromatin.
(Giemsa, ×400). Inset: tumor cells contain ﬁne lipid vacuoles in the
cytoplasm (Giemsa, ×200). (b) Loosely cohesive tumor cells with
nuclear features mimicking malignant hepatocytes (Papanicolaou,
×400). (c) Histology of adrenal tumor shows trabecular-sinusoidal
pattern and polygonal cells with central round nucleus and
nucleolus, mimicking HCC. The cytoplasm shows eosinophilic
granularity (H&E, ×200).
6.3.1. Special Types
(i) HCC, Fibrolamellar Variant. The tumor is character-
ized by monotonous population of discohesive, large
polygonal cells with abundant oncocytic granular
cytoplasm [60, 61]. Individual cells are about three
times larger than normal hepatocytes, as are nuclear
and nucleolar sizes.The nuclear-cytoplasmic ratio is
generally <1/3. Intracytoplasmic pale and hyaline
bodies are common. Presence of collagenous bands
is a distinctive clue.
(ii) HCC, Scirrhous Type. This type is uncommon and
should not be confused with ﬁbrolamellar carcinoma
and cholangiocarcinoma.
(iii) Undiﬀerentiated Type. The tumor cells can be loosely
cohesive or show tendency to dissociation. They are
pleomorphicandnondescriptwithnocytologicclues
to their hepatocytic histogenesis.
(iv) Lymphoepithelioma-Like Carcinoma. It is a rare type
of HCC with small pleomorphic tumor cells admixed
with abundant lymphocytes. In some cases, the
tumor cells are positive for Epstein-Barr virus [53].
(v) Sarcomatoid HCC. The purely sarcomatoid variant is
rare; it is more often seen in conjunction with tumor
giant cells. Extensive sampling may reveal areas of
conventional HCC [58].
6.3.2. Others
(i) Combined Hepatocellular-Cholangiocarcinoma. Alth-
ough this combined (or mixed) tumor is character-
ized byanintimate admixtureof HCC, cholangiocar-
cinoma, and a transitional component, not all com-
ponents need be encountered in FNA material. HCC
and cholangiocarcinoma are easily recognizable.
However, transitional cells with features straddling
HCC and adenocarcinoma may predominate [62,
63]. They may resemble malignant hepatocytes with
trabecular arrangement but also exhibit acini with
nuclear palisading. On the other hand, the transi-
tionalcellsmaydisplaynuclearcontourirregularities,
indistinct nucleolus, and less granular cytoplasm.
There may be diﬃculties distinguishing pseudoacini
from true acini. Mucin may not be detected. The
immunophenotype is often equivocal. A high index
of suspicion is required for this cytodiagnosis.
FNA Biopsy of Highly Well-Diﬀerentiated Hepatocellular
Carcinoma. Diagnostic accuracy is certainly a challenge at
this end of the spectrum and often indeterminate reports
are rendered. Cytologic features predictive of HCC include
increased nuclear-cytoplasmic ratio, cellular monomor-
phism, nuclear crowding, trabeculae >2 cells thick, atypical
naked hepatocytic nuclei, and lack of bile duct cells [26,
51, 64, 65]. Cytologic parameters distinguishing highly
well-diﬀerentiated HCC from cirrhosis include well-deﬁned
cell borders, scant cytoplasm, monotonous cytoplasm,
thick cytoplasm, eccentric nuclei, and increased nuclear-
cytoplasmic ratio [66]. An intimate admixture of neoplasticPathology Research International 13
(a)
(b)
Figure 1 4 :F N Ao fr e s e c t e ds p e c i m e no fm o d e r a t e l yd i ﬀerentiated
hepatocellular carcinoma: conventional smears versus liquid-based
cytology.(a)Leftpanel:Conventionalsmearshowslargerandﬂatter
aggregate of malignant hepatocytes. Right panel: ThinPrep smear
shows a tighter, 3-dimensional cluster of malignant hepatocytes
with trabeculae. The background is devoid of cells. Crisp nuclear
details are better appreciated in monolayered cells. (Papanicolaou,
×400) (b) Left panel: Conventional smear shows malignant hep-
atocytes with bile canaliculi forming a delicate network of criss-
crossing tubules highlighted by immunostaining with polyclonal
CEA. Right panel: The canalicular network is more diﬃcult to
discern in the ThinPrep smear. (pCEA immunostain, ×400).
and nonneoplastic hepatocytes can be encountered in FNA
of “nodule-in-nodule” lesions (Figure 12). Availability of cell
blocks or microbiopsy material is very helpful for ancillary
stains.
6.4. FNA Biopsy of Nonhepatocellular Mimics of
Hepatocellular Carcinoma and Its Variants
6.4.1. Benign Entities
Hepatic Angiomyolipoma. May consist of epithelioid and/or
spindle cells with increased vascularity but without obvious
adipocytes. A high index of suspicion and familiarity with
this entity go a long way to avoiding the common pitfall of
labeling the epithelioid variant with clear or oncocytic cells
as HCC [67, 68]. Immunoreactivity of the tumor cells with
HMB45 and desmin will help clinch the diagnosis.
Inﬂammatory Pseudotumors. Pose a distinct diagnostic pit-
fall clinically, radiologically, and cytomorphologically. Cyto-
logic ﬁndings are highly variable. The pitfall of interest is
mistaking reactive hepatocytes for HCC [69]. One should
exercise extreme caution in making a diagnosis of malig-
nancy in the face of concomitant inﬂammation.
6.4.2. Malignant Entities. A practical approach to adopt
when dealing with hepatic FNA of nonhepatocellular malig-
nancies is to categorize them into the following cytomor-
phologic groups, namely, adenocarcinoma, squamous cell
carcinoma, small round cell tumor, clear cell tumor, or
malignancies characterized by pleomorphic, spindle, giant,
orundiﬀerentiatedcells[21].Theinitialcytologicassessment
is crucial as it forms the impression upon which appropriate
ancillary tests are ordered. Some of these cytomorphologic
entities may occur de novo in the liver. At best, information
gleaned from a precise cytodiagnosis can only favor a
particular primary site. Close clinicopathologic correlation
is mandatory.
Renal cell carcinoma, adrenocortical carcinoma, and
melanomaarewell-documentedmimicsofHCC(Figure 13).
Metastatic and primary hepatic neuroendocrine tumors can
occur [70] .T h ep o l y g o n a lc e l ls u b t y p eo fn e u r o e n d o c r i n e
tumor can mimic well-diﬀerentiated HCC whilst the small
cell subtype can mimic small cell variant of HCC. Epithe-
lioidandspindlevariantsofleiomyosarcoma/gastrointestinal
stromal tumor may simulate HCC and its sarcomatoid
variant, respectively [71, 72]. Rarely, extrahepatic AFP-
producing hepatoid or nonhepatoid carcinomas, arising
most commonly in the gastrointestinal tract, may occur.
They have a proclivity for vascular permeation and liver
metastases, giving rise to confusion with primary AFP-
producing HCC [73].
7.DiagnosticUtilityof Immunohistochemistry
An armamentarium of antibodies is available for the com-
parative immunohistochemical analysis of primary and me-
tastatic tumors of the liver. A panel of immunostains has
more discriminant value. Immunohistochemistry is pre-
ferred to immunocytochemistry. Careful light microscopic
assessment of the histologic sections is important as judi-
cious use of immunostains is imperative since material is
limited. Double-staining protocols may help to optimize
tissue usage.
Kakar et al. outlined best practice guidelines for use
of immunohistochemistry in the diﬀerential diagnosis of
hepaticlesionsunderspeciﬁcclinicalscenarios[74].Stepwise
logistic regression analysis has shown that the panel of
glypican-3, HepPar1, MOC-31, and CK7 is most useful
in diagnosing and distinguishing HCC from metastatic
adenocarcinoma on FNA material, with accuracy rates of14 Pathology Research International
90.5 and 91.7%, respectively [75–78]. In the HCC group,
glypican-3 was the most sensitive (81%), whereas HepPar1
(71.4%) and polyclonal carcinoembryonic antigen (pCEA)
(50%) were less sensitive. In the metastatic adenocarcinoma
group, MOC-31 was most sensitive (79.2) followed by CK7
(41.7%).
In the context of hepatocellular nodular lesions, the
objectives are twofold [79]: (i) to prove hepatocellular
histogenesis and (ii) to demonstrate the malignant status
of the hepatocytes. For the former, the panel should
include Hep Par 1 [80–82], TTF-1 [83, 84], and pCEA
or CD10 to demonstrate canalicular formation (Figure 14)
[85]. For the latter, the panel should include glypican-
3, glutamine synthetase (a target protein of β-catenin),
and heat shock protein 70 (a chaperone stress protein);
two out of three positivity of these novel biomarkers are
taken as indicative of HCC [86–90]. The demonstration
of AFP positivity points towards a malignant tumor of
hepatocellular origin provided nonseminomatous germ cell
tumors and extrahepatic AFP-producing carcinomas have
been excluded. Unfortunately, this tumor marker has such
low sensitivity that it is no longer recommended as part
of the panel [74]. If histologic material is available, use of
CD34 highlights diﬀuse sinusoidal capillarization in HCC
[74, 79]. CK19 can be used to demonstrate the absence of
ductular reaction at the periphery of small HCCs, thereby
conﬁrming stromal invasion at the hepatocellular-stromal
interface. The clinicopathologic and prognostic relevance
of CK7 or 19 expression in HCC as indicative of possible
progenitorcelloriginforthetumorisstillbeingstudied[59].
Immunohistochemical results should always be interpreted
in the larger context of the case.
8. The Future
Ourcytologyroleﬁtsintotheoverallpatientclinicalpathway
as FNA biopsy oﬀers the potential immediacy of a diagnosis
to the clinician who can then advise the patient and develop
an appropriate next clinical step. The rapid turn-around
time or at best reporting within 24 hours is ideal but for
most practices this is not achievable with current resources.
On-site cytology service provides immediate evaluation for
adequacy and triage of specimens, which can be assessed by
cytotechnologists rather than cytopathologists. The reduc-
tion in inadequate sample rates is important for overall cost
eﬀectiveness of the technique.
The future will see a paradigm shift in the perception
of the role of FNA in HCC. New trends in personalized
molecular targeted therapy require better characterization
and prediction of HCC behavior [48]. The FNA biopsy
technique is still the most minimally invasive approach
for the procurement of tumor and peritumoral tissue for
molecular studies. We foresee that in the near future hepatic
FNA is likely to become a point of care in the management of
HCC patients, especially inoperable cases.
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